Pharmacia Zyvox
Executive Summary
Submission to FDA of cases of suspected vancomycin-resistant Enterococcus faecium resistant to linezolid will likely show a lower frequency of documented cases of resistance than reported in an April 14 article in The Lancet. In the 45-patient study, one patient (2.2%) had documented resistance to linezolid in VRE. Pharmacia's reports to FDA will include patients from clinical trials and compassionate-use programs. The company intends to file for the treatment of infections due to penicillin-resistant Streptococcus pneumoniae at the end of 2001 or early 2002
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: